Innocan to Unveil Innovations at Upcoming PAINWeek 2025 Expo
Insights into Innocan Pharma's Participation at PAINWeek 2025
PAINWeek is recognized as the leading U.S. conference dedicated to pain management, drawing experts and healthcare professionals from across the nation. During this high-stakes event, Innocan Pharma Corporation (CSE: INNO) will present a significant poster titled "Is Long-Acting Synthetic Cannabidiol a Solution to Chronic Pain?" This compelling inquiry into synthetic cannabidiol (CBD) is set to showcase important developments in pain relief therapies.
A Showcase of Groundbreaking Research
Innocan's poster will delve into critical data related to the pharmacokinetics and efficacy of their innovative product, LPT-CBD. Accompanying this research is a narrative review that explores the potential of long-acting synthetic cannabidiol for chronic pain management. This review provides key insights into the therapeutic benefits of synthetic CBD in extended-release formulations, steering clear of opioid dependencies while promoting effective pain management alternatives.
Conference Details
PAINWeek 2025 will take place in Las Vegas from September 2 to 5, 2025, an event that is vital for showcasing innovative approaches to pain management and treatment. Innocan's poster presentation is scheduled for the scientific poster reception on September 4, where it will be presented by Dr. Joseph V. Pergolizzi, Jr., a pivotal figure in Innocan's advisory board.
Addressing the Opioid Crisis
In a time where opioid dependency is becoming a major global health concern, Innocan's focus on developing LPT-CBD provides a new perspective on pain management strategies. Supported by promising preclinical studies, LPT-CBD aims to deliver controlled and sustained CBD levels over extended periods while ensuring high tolerability. This innovative approach positions Innocan not just as a participant but as a leader in the search for viable solutions to chronic pain.
Statements from Innocan's Leadership
“We are thrilled to present our findings at PAINWeek, which reflects our dedication to advancing research that can significantly impact patient care in pain management,” stated Iris Bincovich, Chief Executive Officer of Innocan. Her commitment underscores the dedication to advancing non-opioid pain solutions that stem from credible scientific research.
What’s Next for Innocan
As Innocan continues to forge ahead with its promising research, the spotlight at PAINWeek provides an opportunity to connect with healthcare professionals and potential pharmaceutical partners. The company seeks to foster collaborations that can help bring its innovative LPT-CBD product to those who need it the most, reinforcing the importance of accessible and effective pain management alternatives.
Exploring Further
Innocan is not only making strides in pharmaceuticals but also holds a significant place in the wellness sector. From CBD-infused liposomal drug delivery systems to a diverse range of wellness products, Innocan is focused on encouraging healthier lifestyles alongside its pharmaceutical innovations. In addition, their 60% owned subsidiary, BI Sky Global Ltd., emphasizes advanced online sales for wellness products tailored to customer needs.
For those interested in directly engaging with Innocan during PAINWeek, you can arrange meetings for in-depth discussions regarding their innovative products and potential collaborations.
Frequently Asked Questions
1. What is Innocan presenting at PAINWeek 2025?
Innocan will showcase a poster titled "Is Long-Acting Synthetic Cannabidiol a Solution to Chronic Pain?" highlighting their findings on LPT-CBD.
2. Why is the PAINWeek conference significant?
PAINWeek serves as a premier platform for professionals in pain management to exchange innovative ideas and research findings, contributing to the advancement of pain care.
3. What is LPT-CBD?
LPT-CBD is an injectable liposomal drug product developed by Innocan for sustained release of synthetic CBD, aimed at providing a non-opioid alternative for chronic pain management.
4. Who is presenting Innocan's research?
Dr. Joseph V. Pergolizzi, Jr. will present Innocan's poster at the conference, representing the innovative work done by the company in pain management.
5. How can I contact Innocan for more information?
You can reach out to Innocan via email for inquiries and to arrange potential meetings during the conference.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.